Bris­tol-My­ers is scout­ing new com­pa­ny star­tups; Ab­b­Vie and Idera team up to eval­u­ate com­bi­na­tion for HN­SCC

→ Bris­tol-My­ers Squibb has looped in a new part­ner to help scout new com­pa­ny cre­ation op­por­tu­ni­ties. As a lim­it­ed part­ner of Bio­Mo­tiv, the phar­ma gi­ant will work with the drug de­vel­op­ment ac­cel­er­a­tor to fund trans­la­tion­al ven­tures “in dis­ease ar­eas where un­met med­ical needs re­main” — and get first dibs to buy the re­sult­ing star­tups up­on lead iden­ti­fi­ca­tion. The deal gives Bris­tol-My­ers ac­cess to Bio­Mo­tiv’s net­work of aca­d­e­m­ic in­sti­tu­tions and their cut­ting-edge, ear­ly-stage dis­cov­er­ies, said Bruce Car, in­ter­im head of dis­cov­ery re­search.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER